



Supplemental Fig. S9. **A.** Pluripotency- vs. neuron-signifying CpH methylation. Top left: 1-D clustered heatmap of adult neuron and hESC cells and identified 473 high-contrast CpH DMT between these two groups. Bottom left: 2-D cluster using same 473 CpH target module, now including EC and multiple different test groups indicated in color legend. EC, hiPSC, and chimp iPSC (chiPSC) cluster with ESC, while postnatal cortex and cerebellum cluster with FACS-sorted neurons. Neuroblastoma and fetal brain are practically unmethylated for these DMT. Top right: PCA of same groups shows orthogonality of neuronal versus pluripotency methyl-CpH axes: EC, hiPSC, and chiPSC track along the ESC/pluripotency axis, while postnatal cortex and cerebellum lay on the neuronal axis. **B.** Measurement of mCpH-pluri levels in the cancer compendium, EC, and benign pluripotent and neuronal references. Sample numbers and anatomic site for each group are shown on the x-axis. Y-axis is the average methylation level of the mCpH-pluri 256 targets. Note: the three outlier samples in the urogenital system group are embryonal carcinoma cell lines. **C.** CpH methylation in experimental reversion to pluripotency of SE cultivars. Xenograft-generated EC phenotypes from the seminoma-like TCam-2 cell line (this and other seminoma-like samples labeled in red; this and other sample annotations provided in sample color legend) (GSE60787) (Nettersheim et al. 2015) induces CpH methylation. The PCA and heatmap demonstrate greater convergence of EC with ESC/iPSC, and relative loss of CpH-me in TCam-2 and 2102EP, which are nullipotent. Induced gain of potency in xenografted TCam-2 is coupled to CpH-me elevation.